Solution Structures of Chemoenzymatically Synthesized Heparin and Its Precursors

Overview

Journal J Am Chem Soc

Publisher American Chemical Society

Specialty Chemistry

Date 2008 Sep 5

PMID 18767845

Citations 65

Authors

Zhenqing Zhang

Scott A McCallum

Jin Xie

Lidia Nieto

Francisco Corzana

Jesus Jimenez-Barbero

Miao Chen

Jian Liu

Robert J Linhardt

Affiliations

Soon will be listed here.

Abstract

We report the first chemoenzymatic synthesis of the stable isotope-enriched heparin from a uniformly labeled [(13)C,(15)N]N-acetylheparosan (-GlcA(1,4)GlcNAc-) prepared from E. coli K5. Glycosaminoglycan (GAG) precursors and heparin were formed from N-acetylheparosan by the following steps: chemical N-deacetylation and N-sulfonation leading to N-sulfoheparosan (-GlcA(1,4)GlcNS-); enzyme-catalyzed C5-epimerization and 2-O-sulfonation leading to undersulfated heparin (-IdoA2S(1,4)GlcNS-); enzymatic 6-O-sulfonation leading to the heparin backbone (-IdoA2S(1,4)GlcNS6S-); and selective enzymatic 3-O-sulfonation leading to the anticoagulant heparin, containing the GlcNS6S3S residue. Heteronuclear, multidimensional nuclear magnetic resonance spectroscopy was employed to analyze the chemical composition and solution structure of [(13)C,(15)N]N-acetylheparosan, precursors, and heparin. Isotopic enrichment was found to provide well-resolved (13)C spectra with the high sensitivity required for conformational studies of these biomolecules. Stable isotope-labeled heparin was indistinguishable from heparin derived from animal tissues and is a novel reagent for studying the interaction of heparin with proteins.

Citing Articles

Synthesis of bioengineered heparin chemically and biologically similar to porcine-derived products and convertible to low MW heparin.

Douaisi M, Paskaleva E, Fu L, Grover N, McManaman C, Varghese S Proc Natl Acad Sci U S A. 2024; 121(14):e2315586121.

PMID: 38498726 PMC: 10998570. DOI: 10.1073/pnas.2315586121.

Non-anticoagulant heparin derivatives for COVID-19 treatment.

Cao M, Qiao M, Sohail M, Zhang X Int J Biol Macromol. 2022; 226:974-981.

PMID: 36528145 PMC: 9749384. DOI: 10.1016/j.ijbiomac.2022.12.090.

Platelet factor 4 polyanion immune complexes: heparin induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia.

Datta P, Zhang F, Dordick J, Linhardt R Thromb J. 2021; 19(1):66.

PMID: 34526009 PMC: 8443112. DOI: 10.1186/s12959-021-00318-2.

Investigation of the biological functions of heparan sulfate using a chemoenzymatic synthetic approach.

Wang Z, Arnold K, Dhurandhare V, Xu Y, Liu J RSC Chem Biol. 2021; 2(3):702-712.

PMID: 34179782 PMC: 8190904. DOI: 10.1039/d0cb00199f.

Advances in the preparation and synthesis of heparin and related products.

Baytas S, Linhardt R Drug Discov Today. 2020; 25(12):2095-2109.

PMID: 32947045 PMC: 7718634. DOI: 10.1016/j.drudis.2020.09.011.

References

Guerrini M, Guglieri S, Beccati D, Torri G, Viskov C, Mourier P . Conformational transitions induced in heparin octasaccharides by binding with antithrombin III. Biochem J. 2006; 399(2):191-8. PMC: 1609903. DOI: 10.1042/BJ20060656. View

Homans S . Zeneca Award Lecture. New tricks with isotopically enriched oligosaccharides. Biochem Soc Trans. 1999; 26(4):551-60. DOI: 10.1042/bst0260551. View

Pearlman D . How is an NMR structure best defined? An analysis of molecular dynamics distance-based approaches. J Biomol NMR. 2012; 4(1):1-16. DOI: 10.1007/BF00178332. View

Westler W, Stockman B, Hosoya Y, Miyake Y, Kainosho M, Markley J . Correlation of carbon-13 and nitrogen-15 chemical shifts in selectively and uniformly labeled proteins by heteronuclear two-dimensional NMR spectroscopy. J Am Chem Soc. 2011; 110(18):6256-8. DOI: 10.1021/ja00226a057. View

Yu F, Wolff J, Jonathan Amster I, Prestegard J . Conformational preferences of chondroitin sulfate oligomers using partially oriented NMR spectroscopy of 13C-labeled acetyl groups. J Am Chem Soc. 2007; 129(43):13288-97. DOI: 10.1021/ja075272h. View

Ragazzi M, Ferro D, Perly B, Sinay P, Petitou M, CHOAY J . Conformation of the pentasaccharide corresponding to the binding site of heparin for antithrombin III. Carbohydr Res. 1990; 195(2):169-85. DOI: 10.1016/0008-6215(90)84165-q. View

Forster M, Jones C, Mulloy B . NOEMOL: integrated molecular graphics and the simulation of Nuclear Overhauser effects in NMR spectroscopy. J Mol Graph. 1989; 7(4):196-201, 217. DOI: 10.1016/0263-7855(89)80002-5. View

Capila I, Linhardt R . Heparin-protein interactions. Angew Chem Int Ed Engl. 2002; 41(3):391-412. DOI: 10.1002/1521-3773(20020201)41:3<390::aid-anie390>3.0.co;2-b. View

Casu B . Structure and biological activity of heparin. Adv Carbohydr Chem Biochem. 1985; 43:51-134. DOI: 10.1016/s0065-2318(08)60067-0. View

10.

Silipo A, Zhang Z, Canada F, Molinaro A, Linhardt R, Jimenez-Barbero J . Conformational analysis of a dermatan sulfate-derived tetrasaccharide by NMR, molecular modeling, and residual dipolar couplings. Chembiochem. 2007; 9(2):240-52. PMC: 4135520. DOI: 10.1002/cbic.200700400. View

11.

Casu B, Grazioli G, Razi N, Guerrini M, Naggi A, Torri G . Heparin-like compounds prepared by chemical modification of capsular polysaccharide from E. coli K5. Carbohydr Res. 1994; 263(2):271-84. DOI: 10.1016/0008-6215(94)00172-3. View

12.

Mulloy B, Linhardt R . Order out of complexity--protein structures that interact with heparin. Curr Opin Struct Biol. 2002; 11(5):623-8. DOI: 10.1016/s0959-440x(00)00257-8. View

13.

Lindahl U, Li J, Kusche-Gullberg M, Salmivirta M, Alaranta S, Veromaa T . Generation of "neoheparin" from E. coli K5 capsular polysaccharide. J Med Chem. 2005; 48(2):349-52. DOI: 10.1021/jm049812m. View

14.

Linhardt R, Gunay N . Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost. 1999; 25 Suppl 3:5-16. View

15.

Munoz E, Linhardt R . Heparin-binding domains in vascular biology. Arterioscler Thromb Vasc Biol. 2004; 24(9):1549-57. PMC: 4114236. DOI: 10.1161/01.ATV.0000137189.22999.3f. View

16.

Kuberan B, Beeler D, Lech M, Wu Z, Rosenberg R . Chemoenzymatic synthesis of classical and non-classical anticoagulant heparan sulfate polysaccharides. J Biol Chem. 2003; 278(52):52613-21. DOI: 10.1074/jbc.M305029200. View

17.

DeAngelis P, Gunay N, Toida T, Mao W, Linhardt R . Identification of the capsular polysaccharides of Type D and F Pasteurella multocida as unmodified heparin and chondroitin, respectively. Carbohydr Res. 2002; 337(17):1547-52. DOI: 10.1016/s0008-6215(02)00219-7. View

18.

Mikhailov D, Linhardt R, Mayo K . NMR solution conformation of heparin-derived hexasaccharide. Biochem J. 1998; 328 ( Pt 1):51-61. PMC: 1218886. DOI: 10.1042/bj3280051. View

19.

Murugesan S, Park T, Yang H, Mousa S, Linhardt R . Blood compatible carbon nanotubes--nano-based neoproteoglycans. Langmuir. 2006; 22(8):3461-3. PMC: 4114241. DOI: 10.1021/la0534468. View

20.

Guerrini M, Naggi A, Guglieri S, Santarsiero R, Torri G . Complex glycosaminoglycans: profiling substitution patterns by two-dimensional nuclear magnetic resonance spectroscopy. Anal Biochem. 2005; 337(1):35-47. DOI: 10.1016/j.ab.2004.10.012. View